The published clinical pharmacokinetic studies involved patients, who were characterized only as “having liver disease” (without etiology), and those published are in keeping with the merged LC-MS/MS proteomic studies results for the following enzymatic proteins in ALD: CYP1A2 (caffeine), CYP2E1 (chlorzoxazone) and CYP3A4 (midazolam) as well as in HCV: CYP2E1 (chlorzoxazone) and CYP2D6 (debrisoquine) [1,2,3]. This evidence concerns the gene CYP1A2 and liver disorder.